Evidence map›Paper›PMID 34989946›Full record

ArticleJournal of clinical immunology2022

Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients.

Friederike C Schulze Lammers, Agnes Bonifacius, Sabine Tischer-Zimmermann, Lilia Goudeva, Jörg Martens, Bernd Lepenies, Maria von Karpowitz, Gunilla Einecke, Gernot Beutel, Thomas Skripuletz and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Friederike C Schulze Lammers *Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany.
Agnes Bonifacius *Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany.
Sabine Tischer-ZimmermannInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany.
Lilia GoudevaInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany.
Jörg MartensInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany.
Bernd LepeniesInstitute for Immunology & Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, DE, Germany.
Maria von KarpowitzInstitute for Biostatistics, Hannover Medical School, Hannover, DE, Germany.
Gunilla EineckeDepartment of Nephrology, Hannover Medical School, Hannover, DE, Germany.
Gernot BeutelDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, DE, Germany.
Thomas SkripuletzDepartment of Neurology, Hannover Medical School, Hannover, DE, Germany.
Rainer BlasczykInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany.
Rita BeierDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, DE, Germany.
Britta Maecker-KolhoffDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, DE, Germany.
Britta Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, DE, Germany. eiz-vesper.britta@mh-hannover.de.ORCID 0000-0001-8378-3298
Medizinische Hochschule Hannover · DEUniversity of Veterinary Medicine Hannover, Foundation · DE

Funding

Deutsche Forschungsgemeinschaft FOR2830Deutsche Forschungsgemeinschaft SFB900/B11 158989968
6 · The paper itself

Abstract

Viral infections and reactivations are major causes of morbidity and mortality after hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) as well as in patients with immunodeficiencies. Latent herpesviruses (e.g., cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6), lytic viruses (e.g., adenovirus), and polyomaviruses (e.g., BK virus, JC virus) can cause severe complications. Antiviral drugs form the mainstay of treatment for viral infections and reactivations after transplantation, but they have side effects and cannot achieve complete viral clearance without prior reconstitution of functional antiviral T-cell immunity. The aim of this study was to establish normal ranges for virus-specific T-cell (VST) frequencies in healthy donors. Such data are needed for better interpretation of VST frequencies observed in immunocompromised patients. Therefore, we measured the frequencies of VSTs against 23 viral protein-derived peptide pools from 11 clinically relevant human viruses in blood from healthy donors (n = 151). Specifically, we determined the VST frequencies by interferon-gamma enzyme-linked immunospot assay and classified their distribution according to age and gender to allow for a more specific evaluation and prediction of antiviral immune responses. The reference values established here provide an invaluable tool for immune response evaluation, intensity of therapeutic drugs and treatment decision-making in immunosuppressed patients. This data should make an important contribution to improving the assessment of immune responses in immunocompromised patients.

Indexed as

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationVirus DiseasesAntiviral AgentsHerpesvirus 4, HumanHumansImmunocompromised HostReference ValuesT-LymphocytesAntiviral AgentsAdaptive immunityAntiviral T-cell repertoireCellular immunityCellular therapyImmunosuppressionTransplantationVirus-specific T cells

Identifiers

PMID34989946
PMCPMC9015970
OpenAlexW4205448608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.